Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Dreimer200on May 31, 2023 9:08am
196 Views
Post# 35472028

RE:RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements

RE:RE:RE:RE:RE:New Press Release - Theralase(R) Releases 1Q2023 Interim Financial Statements
You are correct. But that peculiar approach to the data is entirely misleading, and – I would argue -- perverse and subversive.
 
The string of greens – followed by a string of reds – can give rise to the following immediate and speculative responses:
 
1. Holy cow! It looks as though everything was hunky-dory. Then they ran into a problem!
 
2. What happened? I thought that TLD stuff had been tested for shelf life! Did they run into a bad batch? Is there something here we haven’t been told about?
 
3. Do all those reds represent the results from sites that are incompetent?
 
4. Why does the company continually appear to wish to obfuscate rather than clarify? Does the person in charge of data presentation have deep-seated, underlying psychological issues? Feels the need to over-organize in order to prove competence? Is simply mindlessly indifferent to the implications? Gets a kick out of watching the confusion – for days or weeks – which follows each release of data?
 
We know -- in fact – that the first 12 patients were under-treated. There was no initial period of hunky-doriness – followed by disaster. The swimmer’s plot should reflect that reality. The fact that it does not is – to be kind – “troubling.”
 
 
 
 
   
 
 
 
 
 
 
<< Previous
Bullboard Posts
Next >>